Visiongain
report announces cannabinoids as a potential blockbuster?
Released on
= April 22, 2005, 8:40 am
Press Release
Author = Senh Ip
Industry = Pharmaceuticals
Press Release
Summary = San Francisco, CA and London, UK; 22 April 2005 visiongain.
According to the latest visiongain report, there is a potential
for a drug within the cannabinoids market to become a blockbuster
within the next few years. The visiongain report, "Cannabinoids:
A Potential Blockbuster?” , states that there are at present
only 2 approved cannabinoid drugs on the market: Canada has recently
become the first country to accept the use of a medicine derived
from cannabis when it is approved GW Pharma’s Sativex for
the relief of pain in multiple sclerosis suffers.
Press Release
Body = Sativex is expected to raise both profits and the profile
of the cannabinoid market. GW Pharmaceutical also hopes Sativex
will become available in the UK by the end of 2005 for MS associated
spasticity and pave the way for approval of the companies many other
cannabinoid pipeline products.
"Sativex,
a trial cannabinoid drug, is expected to generate revenues of $200
million in its first six months following its 2005 launch, by 2006
this is expected to grow 20.0% to $240 million" says Zoe Downes,
visiongain's Pharmaceutical analyst. According to the latest visiongain
report "By 2010, Sativex should be marketed in the US where
profits of $575 million can be expected". With these revenues
Sativex will dominate the cannabinoid market, which currently lies
with Marinol. Visiongain predicts that Acomplia will earn revenues
of $120 million in its first twelve months of launch expected at
the end of 2005. Revenues will grow steadily until 2010, where
they could generate up to $175 million.
Visiongain values
the current cannabinoid market in 2005 at $110.5 million. This value
is the combined world revenues of Marinol, Nabilone and also includes
generic Dronabinol in Germany. This is a 6.3% growth increase from
2004, where revenues totalled $104 million. By 2010 sales of these
products could reach a potential of just under $200 million. Over
the forecast period, 2002 to 2010, this will generate a CAGR% of
10.76%.
By 2006 the
cannabinoid market is expected to develop from the limited,
controversial, niche market of today, to that with a much higher
profile with
additional approved therapeutic areas. The next coming months will
witness the arrival of the world's first whole-cannabis plant derived
pharmaceutical product, Sativex. Sativex (THC:CBN) from the innovative
cannabinoid company GW Pharmaceuticals is expected to be launched
into the Canadian neuropathic pain Multiple Sclerosis market.
Acomplia, (Rimonabant)
by Sanofi-Aventis is another major new comer to the market. Acomplia
is expected to gain approval for the antiobesity/smoking cessation
markets by the end of 2005. Acomplia is also undergoing Phase II
studies for alcohol withdrawal. If Sativex and Acomplia are approved
for MS neuropathic pain/spasticity and antiobesity, the market then
could reach a potential of $947 by 2010 with sales of Marinol and
Nabilone with generic Dronabinol aiding revenues.
# # #
If you are interested
in an overview of cannabinoids: a potential blockbuster - Please
send an email to Senh Ip Senh.ip@visiongain.com including: full
name, Title of publication, contact telephone number, Email, and
details of where you saw this release. Upon receipt of this information,
an overview will be emailed to you. Also view:
http://www.epharmaceuticalnews.com/Products/4/201/visiongain/Cannaboids-A-potential-blockbuster.html
Background:
Visiongain is one of the fastest growing and most innovative independent
media companies in Europe today. Based in London, UK, visiongain
produce a host of business-2-business conferences, newsletters,
management reports and E-Zines focusing on the Financial markets,
the Pharmaceutical, Telecoms industries and currently the Defence
sector.
For more Pharmaceutical
information, please contact our website on:
Http://www.epharmaceuticalnews.comFor
information on visiongain, please visit the website: Http://www.visiongain.com
For additional
information contact:
Senh Ip
Corporate communications
visiongain
40 Tooting High St,
London SW17 ORG, UK
Tel: +44 (0) 20 8767 6711
Fax: +44 (0) 20 8767 5001
Email: Senh.ip@visiongain.com
Web Site = http://www.epharmaceuticalnews.com/Index.html
Contact Details
= 40 Tooting High Street
Tooting
London
020 8767 6711
020 8767 5001
www.visiongain.com
Printer
Friendly Format
Back to previous
page...
Back to home page...
Submit your
press releases...
|